亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

B lymphocyte Vaccines for Cancer

詳細技術說明
Researchers have developed the use of invitro activated B lymphocytes (a type of white blood cell) as a cellularvaccine to fight tumor growth by harvesting B lymphocytes from a patient’sblood sample, then activating these cells in the laboratory via stimuli whichincludes material from the patient’s tumor. The stimulated B cells are then injectedback into the patient, where they serve to activate an immune response thatworks to kill the tumor.  The technologyprovides a simpler, more feasible and effective alternative to the current useof dendritic cells as cellular vaccines for cancer.
*Abstract

Patentinformation:

Patentapplication currently on file with the USPTO (Serial No. 62/132,316).

Background Information

Cancer affects approximately 14.5million people in the United States.  Immunotherapy is a cancer therapythat stimulates the patient's immune system to kill tumor cells.  Cancer vaccines are made up of cancercells, parts of cells, or pure antigens. Once the vaccine is ready, it isinjected into the body to increase the immune response against cancercells. 

Currenttechniques for immunotherapy of cancer rely on use of a patient’s dendriticcells for a vaccine.  However, despite promise in preclinical models, humantrials have been disappointing. A major problem is that it ischallenging to obtain sufficient numbers of dendritic cells for effectivenessas these cells are not common in the body and cannot be replicated outside the body using currenttechniques. Researchers have discovered that a promising alternative is Bcells, abundant in the blood and easily expanded in culture.

Technology Summary

Researchers have developed the use of invitro activated B lymphocytes (a type of white blood cell) as a cellularvaccine to fight tumor growth by harvesting B lymphocytes from a patient’sblood sample, then activating these cells in the laboratory via stimuli whichincludes material from the patient’s tumor. The stimulated B cells are then injectedback into the patient, where they serve to activate an immune response thatworks to kill the tumor.  The technologyprovides a simpler, more feasible and effective alternative to the current useof dendritic cells as cellular vaccines for cancer.

Advantages

·        Easeof production.

o  Itis easier to isolate B cells from blood than dendritic cells currently used forimmunotherapy.

o  Bcells reproduce more easily than dendritic cells.

·        Reducedrisk.

o  Isolationof cells from a patient during activation of B lymphocytes reduces the risksassociated with current stimulation methods.

*Licensing
Zev SunleafExecutive DirectorUniversity of Iowa Research FoundationPhone: 319-335-4155zev-sunleaf@uiowa.eduZev SunleafExecutive DirectorUniversity of Iowa Research FoundationPhone: 319-335-4155zev-sunleaf@uiowa.edu
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備